Using single-cell transcriptomics to predict which tumors will respond to targeted therapy

IF 23.5 1区医学 Q1 ONCOLOGY

Nature cancer Pub Date : 2024-04-29 DOI:10.1038/s43018-024-00757-6

引用次数: 0

Abstract

We performed a proof-of-concept study showing that single-cell RNA sequencing, a method for capturing rich tumor information (not yet in clinics owing to high costs), can be used to identify patients likely to respond to targeted therapy and to monitor the emergence of resistance.

Abstract Image

查看原文本刊更多论文

利用单细胞转录组学预测哪些肿瘤会对靶向疗法产生反应

我们进行了一项概念验证研究，结果表明单细胞 RNA 测序是一种捕捉丰富肿瘤信息的方法（由于成本高昂，尚未应用于临床），可用于识别可能对靶向治疗产生反应的患者，并监测耐药性的出现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature cancer Medicine-Oncology

CiteScore

31.10

自引率

1.80%

发文量

129

期刊介绍： Cancer is a devastating disease responsible for millions of deaths worldwide. However, many of these deaths could be prevented with improved prevention and treatment strategies. To achieve this, it is crucial to focus on accurate diagnosis, effective treatment methods, and understanding the socioeconomic factors that influence cancer rates. Nature Cancer aims to serve as a unique platform for sharing the latest advancements in cancer research across various scientific fields, encompassing life sciences, physical sciences, applied sciences, and social sciences. The journal is particularly interested in fundamental research that enhances our understanding of tumor development and progression, as well as research that translates this knowledge into clinical applications through innovative diagnostic and therapeutic approaches. Additionally, Nature Cancer welcomes clinical studies that inform cancer diagnosis, treatment, and prevention, along with contributions exploring the societal impact of cancer on a global scale. In addition to publishing original research, Nature Cancer will feature Comments, Reviews, News & Views, Features, and Correspondence that hold significant value for the diverse field of cancer research.